CONTRACT FOR CARE · RIGHTS, CONSENT & GOVERNMENT POWER
Our Legal Case
A patient’s need for medicine should not become the pressure used to obtain a criminal admission. Examine compulsory disclosures, penalties for silence, coerced rights waivers, and the circumstances behind the signature.
Use the original agreement and policy sources for this record to identify the exact clause, its legal source, and the stated consequence. Preserve those facts before reaching a conclusion about a particular provider or condition.
Apply the constitutional and consent review to this record
- Government responsibility: Which law, binding rule, agency instruction, or public-provider policy requires the particular disclosure or consequence? Separate it from provider-added terms.
- Potential criminal admission: Identify the exact spoken answer, written history, certification, or explanation and the real criminal risk it creates.
- Penalty for silence: Record what happens if the patient invokes the privilege or refuses a rights waiver, including denial, discharge, or interruption of treatment.
- Consent and pressure: Preserve the circumstances of signing, severity of pain, accessible alternatives, and whether the patient could honestly accept the prospective obligations.
- Criminal-use protection: Identify legally sufficient immunity and limits on use of both the answer and evidence derived from it. A privacy assurance is a separate protection.
Read the precedents, evidence framework, clause review, and remedies and reform demands. The work develops a proposed constitutional challenge; applying it to a particular condition requires its facts and legal authority.
MASSACHUSETTS · CONTRACT FOR CARE
Pain and Wellness Center — Controlled Substance Policy
Public institutional form — current signed use unconfirmed
Document/version: URL/filename2026/06 and2026; PDF metadata title says2025; no printed effective date. 2 PDF pages.
Current website link verified; June2026 path is upload evidence, not effective-date or operative-use proof. Filename/title-year conflict retained. Separate refill webpage requires office visit for controlled medicines.
Selected exact excerpt (p.2, §14): all confidentiality is waived
.
Requirements and documented consequences
This table paraphrases source-located terms. Use the original PDF for exact complete wording. PDF page numbers count from the first page, including packet covers.
| Source location | Requirement summary | Classification | Stated consequence |
|---|---|---|---|
| p.1, §§1–2 | Clinic prescribers unless authorized; one pharmacy where possible, notify changes. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.1, §§3,5 | Report medicines/conditions/effects; permit care-team/pharmacy discussions. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.1, §4 | No alcohol/recreational drugs. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.1, §§6,9,11 | No sharing/sale; safeguard medicines, restrict others' access. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.1, §7 | Warns against abrupt stopping. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.1, §8 | Unannounced urine/serum screens; unauthorized substances may prompt referral/discontinuation. | Clinic term beyond §18A baseline | Possible controlled-substance discontinuation. |
| p.1, §10 | Bring unused medicines in original containers at visits or random requests. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.2, §§12–13 | Loss may not be replaced; theft report may permit exception; generally no early refills. | Clinic term beyond §18A baseline | Possible nonreplacement. |
| p.2, §14 | Broad confidentiality waiver for legal-authority questions. | Legal review required | Reach and validity unresolved. |
| p.2, §15 | Failure may end controlled prescribing or trigger referral. | Clinic term beyond §18A baseline | Possible cessation/referral. |
| p.2, §16 | Renewals depend on visits; no after-hours/weekend calls. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.2, §17 | Continuation depends on benefit. | Clinic term beyond §18A baseline | No distinct penalty specified here. |
| p.2, §18 | Participate in other-provider consultations/treatment. | Clinic term beyond §18A baseline | Participation condition. |
Separate refill policy
The refill webpage requires an office visit for controlled substances. Its two-to-three-business-day processing statement concerns routine, non-controlled medications; it is not an opioid processing promise.
Comparison with Massachusetts authority
M.G.L. c.94C §18A(b) requires an agreement addressing benefits and abuse/misuse risks when a registered practitioner recommends ER/LA opioids during long-term pain management. Record placement follows that subsection. Narrow hydrocodone professional rules, written informed-consent duties, and MassHealth coverage criteria are separate layers.
§18A does not itself prescribe these exact deadlines, charges, disclosure terms or dismissal mechanics. 243CMR2.07(25) addresses screening, counts and safe storage for a narrow formulation and patient-specific risk; §2.07(26) separately governs informed consent. A required subject does not make every implementation mandatory.
DIA’s October 2024 chronic-pain guideline addresses agreements, bilateral responsibilities and continuity within the injured-worker context. DIA says its guidelines are not mandates. Coverage terms must be mapped to the actual payer/program.
Connected offices
- Pain and Wellness Center — Peabody — association, not confirmed signed use.
Current copy and practice response
Patients can submit the version presented to them. Practices can supply a current blank form, dates, applicable offices/groups, exceptions and corrections. Historical versions remain linked. No motive or legality finding is made. Privacy, termination, pregnancy-testing and partial-fill interpretations remain open for owner/legal review.
Research: October 12, 2026. Methodology. Factual comparison published with stated interpretation limits.